Amoy Diagnostics Co., Ltd. (SZSE: 300685)
Health Care · Biotechnology · CN
CN¥21.34
+2.55% today · -7.1% 1Y
Amoy Diagnostics Co., Ltd. (SZSE: 300685) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.21B and employs 1,175 people.
Over the last twelve months the share price has lost 7.1%, trading between 15.62 and 24.13.
Tweenvest scores Amoy Diagnostics Co., Ltd. across four factors: quality 81/100, value 62/100, growth 77/100, dividend 24/100. Its strongest factor is quality.
300685 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.21B
- Revenue (TTM)
- $173.38M
- P/E
- 25.37
- EPS
- 0.84
- Dividend yield
- 2.11%
- Beta (5Y)
- 0.31
- 52-week high
- CN¥24.13
- 52-week low
- CN¥15.62
- Avg volume (3M)
- —
- Shares outstanding
- 381.55M
- Employees
- 1,175
- Next earnings
- —
About Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. is a Chinese company focused on oncology precision medicine. It engages in the research, development, production, and sale of molecular diagnostic products. The company provides a range of diagnostic reagents and testing services that help identify genetic mutations and biomarkers, which are used to guide personalized cancer treatment.
- ISIN
- CNE1000034D3
- Founded
- 2008
- Listed since
- Aug 3, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Savara Inc.NasdaqGS: SVRA | $1.24B | $4.88 | +4.95% |
| HOB Biotech Group Corp.,LtdSHSE: 688656 | $1.23B | CN¥131.72 | -0.33% |
| Replimune Group, Inc.NasdaqGS: REPL | $1.23B | $13.20 | +0.99% |
| MannKind CorporationNasdaqGM: MNKD | $1.22B | $3.45 | -9.21% |
| Daan Gene Co., Ltd.SZSE: 002030 | $1.20B | CN¥5.75 | +1.41% |
| Aimed Bio Inc.KOSDAQ: A0009K0 | $1.19B | ₩24,800.00 | +15.89% |
| NatureCell Co.,Ltd.KOSDAQ: A007390 | $1.18B | ₩24,750.00 | +0.41% |
| Suzhou Ribo Life Science Co., Ltd.SEHK: 6938 | $1.18B | HK$54.30 | +3.82% |
Figures last refreshed Oct 4, 2026.